Latest & greatest articles for pioglitazone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pioglitazone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pioglitazone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pioglitazone

41. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study 21410628 2011 05 24 2011 09 14 2015 11 19 1463-1326 13 7 2011 Jul Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo (...) -controlled study. 653-61 10.1111/j.1463-1326.2011.01391.x To compare the efficacy, safety and tolerability of linagliptin or placebo administered for 24 weeks in combination with pioglitazone in patients with type 2 diabetes mellitus (T2DM) exhibiting insufficient glycaemic control (HbA1c 7.5-11.0%). Patients were randomized to receive the initial combination of 30 mg pioglitazone plus 5 mg linagliptin (n = 259) or pioglitazone plus placebo (n = 130), all once daily. The primary endpoint was change from

EvidenceUpdates2011

43. Pioglitazone for Diabetes Prevention.

Pioglitazone for Diabetes Prevention. Pioglitazone for diabetes prevention. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21751925 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Jul 14;365(2):183; author reply 183-4. doi: 10.1056/NEJMc1104572#SA2. Pioglitazone for diabetes prevention. , . Comment on [N Engl J Med. 2011] PMID: 21751925 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links

NEJM2011 Full Text: Link to full Text with Trip Pro

44. Pioglitazone for Diabetes Prevention.

Pioglitazone for Diabetes Prevention. Pioglitazone for diabetes prevention. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21751926 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Jul 14;365(2):182-3; author reply 183-4. doi: 10.1056/NEJMc1104572#SA1. Pioglitazone for diabetes prevention. , . Comment on [N Engl J Med. 2011] PMID: 21751926 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links

NEJM2011 Full Text: Link to full Text with Trip Pro

45. Effects of pioglitazone vs metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes - a randomized controlled trial

Effects of pioglitazone vs metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes - a randomized controlled trial 21255215 2011 10 24 2012 01 09 2013 11 21 1463-1326 13 5 2011 May Diabetes, obesity & metabolism Diabetes Obes Metab Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial. 439-45 10.1111/j (...) .1463-1326.2011.01367.x Endothelial microparticles (EMPs) and endothelial progenitor cells (EPCs) are markers of endothelial injury and repair. We compared the effects of pioglitazone versus metformin on the circulating numbers of EMPs and EPCs in patients with newly diagnosed type 2 diabetes. This was a randomized, double-blind, comparator-controlled, 24-week single-centre trial conducted in a Teaching Hospital in Naples, Italy. One hundred and ten people with newly diagnosed type 2 diabetes who

EvidenceUpdates2011

46. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes 21235696 2011 01 17 2011 12 22 2015 11 19 1742-1241 65 2 2011 Feb International journal of clinical practice Int. J. Clin. Pract. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients (...) with type 2 diabetes. 154-64 10.1111/j.1742-1241.2010.02589.x To assess the safety and efficacy of initial combination therapy with sitagliptin and pioglitazone compared with pioglitazone monotherapy in drug-naïve patients with type 2 diabetes. A total of 520 patients were randomised to initial combination therapy with sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. or pioglitazone 30 mg q.d. monotherapy for 24 weeks. Initial combination therapy with sitagliptin and pioglitazone led to a mean reduction from

EvidenceUpdates2011

47. Pioglitazone for diabetes prevention in impaired glucose tolerance.

Pioglitazone for diabetes prevention in impaired glucose tolerance. 21428766 2011 03 24 2011 04 04 2012 11 15 1533-4406 364 12 2011 Mar 24 The New England journal of medicine N. Engl. J. Med. Pioglitazone for diabetes prevention in impaired glucose tolerance. 1104-15 10.1056/NEJMoa1010949 Impaired glucose tolerance is associated with increased rates of cardiovascular disease and conversion to type 2 diabetes mellitus. Interventions that may prevent or delay such occurrences are of great (...) clinical importance. We conducted a randomized, double-blind, placebo-controlled study to examine whether pioglitazone can reduce the risk of type 2 diabetes mellitus in adults with impaired glucose tolerance. A total of 602 patients were randomly assigned to receive pioglitazone or placebo. The median follow-up period was 2.4 years. Fasting glucose was measured quarterly, and oral glucose tolerance tests were performed annually. Conversion to diabetes was confirmed on the basis of the results

NEJM2011

48. Pioglitazone: risk of bladder cancer

Pioglitazone: risk of bladder cancer Pioglitazone: risk of bladder cancer Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Pioglitazone: risk of bladder cancer From: Published: 8 August 2011 Therapeutic area: Use of pioglitazone is associated with a small increased risk of bladder cancer. Healthcare professionals should be aware of new warnings and precautions for use in at-risk patients Article date: August 2011 Pioglitazone (Actos▼) is an oral treatment (...) for type 2 diabetes, either on its own or combined with other oral antidiabetic agents or insulin. It is also available as a combination tablet with metformin (Competact▼). Risk of bladder cancer The potential risk of bladder cancer with pioglitazone was first identified at the time of licensing, observed in male rats in an animal toxicity study that supported the initial licence application. There was no evidence of a similar risk in humans at that time. The marketing authorisation (licence) holder committed

MHRA Drug Safety Update2011

49. Insulin combined with pioglitazone: risk of cardiac failure

Insulin combined with pioglitazone: risk of cardiac failure Insulin combined with pioglitazone: risk of cardiac failure Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Insulin combined with pioglitazone: risk of cardiac failure From: Published: 12 January 2011 Therapeutic area: If pioglitazone is used in combination with insulin patients should be observed for signs and symptoms of heart failure, weight gain, and oedema. Article date: January 2011 Pioglitazone (...) is indicated for the treatment of type 2 diabetes either as monotherapy (brand name Actos▼) or in combination with metformin (brand name Competact▼) and/or a sulphonylurea. Pioglitazone is also indicated in combination with insulin for adults with type 2 diabetes with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. A European review of the increased incidence of cardiac failure when pioglitazone is used in combination with insulin

MHRA Drug Safety Update2011

50. The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis

The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis Tan A, Cao Y, Xia N, Mo Z, Gao F CRD summary This review concluded that pioglitazone may improve glucose metabolism and lipid parameters in patients with type 2 diabetes inadequately (...) controlled on insulin. The inappropriate synthesis employed means that the authors' conclusions should be treated with a considerable degree of caution since they are not based on randomised data. Authors' objectives To assess the impact of pioglitazone on glycaemic control and lipid parameters, together with the risk of adverse events, when incorporated into the treatment regimen of patients with type 2 diabetes inadequately controlled on insulin. Searching PubMed, EMBASE and the Cochrane Library were

DARE.2010

51. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. 20580422 2010 08 09 2010 08 24 2015 11 19 1474-547X 376 9739 2010 Aug 07 Lancet (London, England) Lancet Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. 431-9 10.1016/S0140-6736(10)60590-9 Most (...) patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin. In this 26-week randomised, double-blind, double-dummy, superiority trial, patients with type 2 diabetes who had been treated

Lancet2010

52. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. 20427778 2010 05 06 2010 05 13 2016 12 15 1533-4406 362 18 2010 May 06 The New England journal of medicine N. Engl. J. Med. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. 1675-85 10.1056/NEJMoa0907929 Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease. We randomly assigned 247 adults with nonalcoholic (...) steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96 weeks. The primary outcome was an improvement in histologic features of nonalcoholic steatohepatitis, as assessed with the use of a composite of standardized scores for steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis. Given the two planned primary comparisons, P values of less than 0.025 were considered

NEJM2010 Full Text: Link to full Text with Trip Pro

53. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial

Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial 19380660 2009 04 21 2009 05 18 2013 11 21 1538-3652 145 4 2009 Apr Archives of dermatology Arch Dermatol Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical (...) trial. 387-93 10.1001/archdermatol.2009.5 To evaluate the efficacy and safety of combination therapy with acitretin and pioglitazone hydrochloride in patients with moderate to severe chronic plaque-type psoriasis. Randomized, double-blind, placebo-controlled clinical trial. A tertiary care referral hospital. Patients The study included patients of either sex (age range, 18-65 years) with moderate to severe chronic plaque-type psoriasis. Patients were excluded if they were of child-bearing potential

EvidenceUpdates2009

54. Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus

Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus 19349323 2009 04 21 2009 05 08 2016 11 25 1524-4539 119 15 2009 Apr 21 Circulation Circulation Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism (...) in patients with well-controlled type 2 diabetes mellitus. 2069-77 10.1161/CIRCULATIONAHA.108.803916 Cardiac disease is the leading cause of mortality in type 2 diabetes mellitus (T2DM). Pioglitazone has been associated with improved cardiac outcome but also with an elevated risk of heart failure. We determined the effects of pioglitazone on myocardial function in relation to cardiac high-energy phosphate, glucose, and fatty acid metabolism and triglyceride content in T2DM patients. Seventy-eight T2DM men

EvidenceUpdates2009

55. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting

Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting Brandle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WF Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of adding pioglitazone to the existing treatment regimens for adult patients with type 2 diabetes and evidence of macrovascular disease. The authors concluded that adding pioglitazone to the current treatment

NHS Economic Evaluation Database.2009

56. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of adding pioglitazone to the existing treatment for adult patients with type 2 diabetes and with evidence of macrovascular disease. The authors concluded that adding pioglitazone

NHS Economic Evaluation Database.2009

57. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive

Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the costs and clinical outcomes of treating patients with pioglitazone in addition to their existing medications for type 2 diabetes with macrovascular complications. The authors concluded

NHS Economic Evaluation Database.2009

58. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis

Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis Clar C, Royle P, Waugh N CRD summary The review concluded that when added to insulin regimens, pioglitazone conferred a small advantage in terms of glycated haemoglobin (...) in type 2 diabetes patients with previous inadequate glucose control, but at the cost of increased hypoglycaemia and weight gain. The review was well conducted and the authors' conclusions appear likely to be reliable. Authors' objectives To investigate the extent to which adding pioglitazone to insulin-containing regimens affects glycaemic control, hypoglycaemia, weight change, lipids, and adverse events. Searching MEDLINE, EMBASE, and the Cochrane Library were searched for studies published between 1996

DARE.2009

59. Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy

Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy 19029503 2008 11 25 2008 12 18 2014 11 20 1538-3679 168 21 2008 Nov 24 Archives of internal medicine Arch. Intern. Med. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. 2368-75 10.1001/archinte.168.21.2368 Recent meta-analyses have raised the possibility that rosiglitazone maleate may increase (...) the risk of ischemic cardiovascular events, whereas pioglitazone hydrochloride could not be linked to such a risk. We compared cardiovascular outcomes and mortality between patients initiating pioglitazone vs rosiglitazone therapy. We assembled an inception cohort of Medicare beneficiaries older than 65 years with state-sponsored prescription drug benefits who had diabetes mellitus and initiated treatment with rosiglitazone or pioglitazone between January 1, 2000, and December 31, 2005. The study

EvidenceUpdates2008

60. Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis 18718471 2008 10 20 2008 11 14 2012 11 15 1528-0012 135 4 2008 Oct Gastroenterology Gastroenterology Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. 1176-84 10.1053/j.gastro.2008.06.047 Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease for which there is limited therapy available. Insulin (...) sensitizing, anti-inflammatory, and antifibrotic properties of thiazolidinediones support their use in treating NASH. We have evaluated pioglitazone in the treatment of nondiabetic patients with NASH. We randomized 74 nondiabetic patients (45 men; median age, 54 y) with histologically proven NASH to 12 months of standard diet, exercise, and either placebo or pioglitazone (30 mg/day). Sixty-one patients (30 placebo, 31 pioglitazone) had liver biopsies both at the beginning and the end of the study

EvidenceUpdates2008